Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma already has the primary FDA approval for a remedy that goes after Claudin 18.2, a protein whose overexpression...
Ghilaf
Showing the single result
